In the search of new therapeutic strategies limiting the risk of tuberculosis reactivation, our previous studies showed that targeting selectively soluble TNF but sparing membrane TNF by Dominant Negative-TNF inhibitor molecules did not compromise immune responses to both M. bovis BCG and M. tuberculosis infections in contrast to other TNF neutralizing molecules [42], while efficiently protecting mice against acute inflammatory reactions [30]. Here, TNF is linked to tuberculosis.